Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-47.
Messiou C, Cook G, deSouza NM. Imaging metastatic bone disease from carcinoma of the prostate. Br J Cancer 2009;101:1225-32.
Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584-93. (Pubitemid 37328925)
Goya M, Ishii G, Miyamoto S, et al. Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer. Prostate 2006;66:1573-84. (Pubitemid 44646349)
Coleman RE, Guise TA, Lipton A, et al. Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference. Clin Cancer Res 2008; 14:6387-95.
Hayward JL, Carbone PP, Heusen JC, et al. Assessment of response to therapy in advanced breast cancer. Br J Cancer 1977;35:292-8.
Hamaoka T, Madewell JE, Podoloff DA, et al. Bone imaging in metastatic breast cancer. J Clin Oncol 2004;22:2942-53. (Pubitemid 41079914)
Hamaoka T, Costelloe CM, Madewell JE, et al. Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer. Br J Cancer 2010;102:651-7.
Vinholes J, Coleman R, Lacombe D, et al. Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion. European Organization for Research and Treatment of Cancer. Br J Cancer 1999;80:221-8. (Pubitemid 29210110)
Blomqvist C, Risteli L, Risteli J, et al. Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma. Br J Cancer 1996;73:1074-9. (Pubitemid 26131227)
Chen SS, Chen KK, Lin AT, et al. Correlation between pretreatment serum biochemical markers and 324 Collignon et al treatment outcome for prostatic cancer with bony metastasis. J Chin Med Assoc 2009;72:301-6.
Pneumaticos SG, Chatziioannou SN, Savvidou C, et al. Routine needle biopsy during vertebral augmentation procedures. Is it necessary? Eur Spine J 2010. [Epub ahead of print].
Datir A, Pechon P, Saifuddin A. Imaging-guided percutaneous biopsy of pathologic fractures: a retrospective analysis of 129 cases. AJRAmJ Roentgenol 2009;193:504-8.
van de Wouw AJ, Janssen-Heijnen ML, Coebergh JW, et al. Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in southeast Netherlands, 1984-1992. Eur J Cancer 2002;38:409-13. (Pubitemid 34121969)
Rosenthal DI. Radiologic diagnosis of bone metastases. Cancer 1997;80:1595-607. (Pubitemid 27444032)
Koizumi M, Matsumoto S, Takahashi S, et al. Bone metabolic markers in the evaluation of bone scan flare phenomenon in bone metastases of breast cancer. Clin Nucl Med 1999;24:15-20. (Pubitemid 29024655)
Coombes RC, Dady P, Parsons C, et al. Assessment of response of bone metastases to systemic treatment in patients with breast cancer. Cancer 1983; 52:610-4. (Pubitemid 13025910)
Beheshti M, Langsteger W, Fogelman I. Prostate cancer: role of SPECT and PET in imaging bone metastases. Semin Nucl Med 2009;39:396-407.
Janicek MJ, Hayes DF, Kaplan WD. Healing flare in skeletal metastases from breast cancer. Radiology 1994;192:201-4. (Pubitemid 24191545)
Elgazzar AH, Kazem N. Metastatic bone disease: evaluation by functional imaging in correlation with morphologic modalities. Gulf J Oncolog 2009; Jan(5):9-21.
Muindi J, Coombes RC, Golding S, et al. The role of computed tomography in the detection of bone metastases in breast cancer patients. Br J Radiol 1983;56:233-6. (Pubitemid 13119074)
Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999;35:1773-82. (Pubitemid 29512308)
Schirrmeister H. Detection of bone metastases in breast cancer by positron emission tomography. Radiol Clin North Am 2007;45:669-76, vi. (Pubitemid 47238392)
Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009; 50(Suppl 1):122S-50S.
Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999;94:429-33. (Pubitemid 29323856)
Jerusalem G, Beguin Y. The place of positron emission tomography imaging in the management of patients with malignant lymphoma. Haematologica 2006;91:442-4.
Couturier O, Jerusalem G, N'Guyen JM, et al. Sequential positron emission tomography using [18F]fluorodeoxyglucose for monitoring response to chemotherapy in metastatic breast cancer. Clin Cancer Res 2006;12:6437-43. (Pubitemid 44799716)
Tateishi U, Gamez C, Dawood S, et al. Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. Radiology 2008;247:189-96.
Specht JM, Tam SL, Kurland BF, et al. Serial 2-[18F]fluoro-2-deoxy-D- glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP). Breast Cancer Res Treat 2007;105:87-94. (Pubitemid 47282751)
Fogelman I, Cook G, Israel O, et al. Positron emission tomography and bone metastases. Semin Nucl Med 2005;35:135-42. (Pubitemid 40568746)
Dehdashti F, Flanagan FL, Mortimer JE, et al. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogentherapy.EurJNuclMed1999;26:51-6. (Pubitemid 29137739)
Mortimer JE, Dehdashti F, Siegel BA, et al. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 2001;19: 2797-803. (Pubitemid 32538187)
Krupitskaya Y, Eslamy HK, Nguyen DD, et al. Osteoblastic bone flare on F18-FDG PET in non-small cell lung cancer (NSCLC) patients receiving bevacizumab in addition to standard chemotherapy. J Thorac Oncol 2009;4:429-31.
Weber WA. Assessing tumor response to therapy. J Nucl Med 2009;50(Suppl 1):1S-10S.
Du Y, Cullum I, Illidge TM, et al. Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer. J Clin Oncol 2007;25: 3440-7. (Pubitemid 47310881)
Berstein L,Maximov S, Gershfeld E, et al.Neoadjuvant therapy of endometrial cancer with the aromatase inhibitor letrozole: endocrine and clinical effects. Eur J Obstet Gynecol Reprod Biol 2002;105:161-5.
Lockhart AC, Rothenberg ML, Dupont J, et al. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol 2010;28: 207-14.
Bauerle T, Bartling S, Berger M, et al. Imaging antiangiogenic treatment response with DCE-VCT, DCE-MRI and DWI in an animal model of breast cancer bone metastasis. Eur J Radiol 2010;73:280-7.
Wang X, Tangjitgamol S, Liu J, et al. Response of recurrent uterine high-grade malignant mixed mullerian tumor to letrozole. Int J Gynecol Cancer 2005;15:1243-8. (Pubitemid 43110194)
Bouchelouche K, Oehr P. Positron emission tomography and positron emission tomography/computerized tomography of urological malignancies: an update review. J Urol 2008;179:34-45. (Pubitemid 350225698)
